Silence Therapeutics, AstraZeneca Extend Research Deal
14th Jul 2010 07:32
LONDON (Dow Jones)--Biotechnology company Silence Therapeutics PLC (SLN.LN) said Wednesday it extended a research deal with AstraZeneca PLC (AZN.LN) by another year. Silence specializes in RNA interference, an experimental branch of drug research which involves shutting off or silencing genes in
Read more2nd UPDATE: Calif Supreme Court Reinstates Suit Vs Drug Cos
13th Jul 2010 22:19
(Adds comment from Pfizer in the last paragraph.) By Peter Loftus Of DOW JONES NEWSWIRES The California Supreme Court has reinstated a lawsuit in which retail pharmacies accused Pfizer Inc. (PFE), AstraZeneca PLC (AZN, AZN.LN) and other major drug makers of conspiring to set prices at ar
Read moreUPDATE: Calif. Supreme Court Clears Price-Fixing Suit Vs. Drug Makers
13th Jul 2010 17:54
(Adds details from court ruling beginning in fifth paragraph; comments for attorneys from both sides and company comments beginning in seventh paragraph) By Peter Loftus Of DOW JONES NEWSWIRES The California Supreme Court has reinstated a lawsuit in which retail pharmacies accused Pfizer
Read moreUPDATE: Investor Says Value Of Investments Up In 2Q
13th Jul 2010 08:37
(Adds detail, comment.) By Erik Durhan Of DOW JONES NEWSWIRES STOCKHOLM (Dow Jones)--Investor AB (INVE-B.SK), the investment vehicle of the Swedish Wallenberg family, Tuesday said the value of its investments rose 3.7% in the three months to June 30, driven mainly by growth in its core
Read moreIndia AstraZeneca Set INR576.10 A Share Floor Price For Delisting
6th Jul 2010 14:06
MUMBAI (Dow Jones)--AstraZeneca Pharma India Ltd. (506820.BY) said Tuesday its founder AstraZeneca Pharmaceuticals AB has set a floor price of INR576.10 a share to buyout a 10% free float and delist the company. The Swedish parent has also set a tentative maximum price of INR1,152.00 a share.
Read moreAstraZeneca Teams Up With MRC Technology In Drug Search
5th Jul 2010 09:44
LONDON (Dow Jones)--U.K. drug maker AstraZeneca PLC (AZN.LN) said Monday it teamed up with the commercial arm of the U.K.'s Medical Research Council to scour a library of about 150,000 compounds for possible drug applications. AstraZeneca said the collaboration will search for compounds that sho
Read moreMARKET TALK: Novartis Near Fair Value: Strong Franc Weighs
5th Jul 2010 07:48
0648 GMT [Dow Jones] Novartis (NVS) is close to being fairly valued but the sharp decline in EUR/CHF will start to hit the pharmaceutical company with its heavy Swiss cost base, says Kepler. "Although we are negative on the stock, the fundamentals are starting to give some support and unlike AstraZe
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
2nd Jul 2010 13:54
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1254 GMT [Dow Jones] Societe Generale lifts AstraZeneca (AZN.LN) price target to 3150p from 2850p after the company's Crestor
Read moreMARKET TALK: Societe Generale Lifts AstraZeneca Price Target
2nd Jul 2010 13:54
1254 GMT [Dow Jones] Societe Generale lifts AstraZeneca (AZN.LN) price target to 3150p from 2850p after the company's Crestor patent win. Says all major US patent litigation has now been resolved in AstraZeneca's favor, with Crestor looking secure until '16, Nexium until '14 and Seroquel until '12.
Read moreUK MARKET TALK ROUNDUP: SHARES LOSING
1st Jul 2010 11:37
Stocks on the fall in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1037 GMT [Dow Jones] Charles Stanley upgrades AstraZeneca (AZN.LN) to accumulate from reduce following the company's victo
Read moreMARKET TALK: Charles Stanley Ups AstraZeneca To Accumulate
1st Jul 2010 11:37
1037 GMT [Dow Jones] Charles Stanley upgrades AstraZeneca (AZN.LN) to accumulate from reduce following the company's victory in the Crestor patent case. Says the decision removes overhang in the share price. "Investors should be aware of the significance of the ruling given that Crestor is without d
Read moreUPDATE: AstraZeneca Loses Bid To Overturn Antitrust Fine
1st Jul 2010 11:20
(Updates on AstraZeneca's bid to have fine overturned, adds detail.) By Mike Gordon and Carolyn Henson Of DOW JONES NEWSWIRES LUXEMBOURG (Dow Jones)--AstraZeneca PLC (AZN) Thursday lost its bid to overturn an antitrust fine imposed on the pharmaceuticals giant in 2005 for trying to squee
Read moreEU Court Cuts Astrazeneca Antitrust Fine To EUR52.5M Vs EUR60M
1st Jul 2010 08:52
LUXEMBOURG (Dow Jones)--A European Union court Thursday reduced an antitrust fine against AstraZeneca (AZN) and its Swedish subsidiary AstraZeneca AB for abusing their dominant position in the market by trying to prevent generic competition for ulcer drug Losec to EUR52.5 million from EUR60 million.
Read moreThursday's tips round-up: Hunting, Astra, Barclays
1st Jul 2010 06:51
Hunting's broad global spread should insulate it against turbulence related to the crisis in the Gulf. And despite a multiple of 26 times 2010 forecasts, the shares are off 33 per cent since their March peak. The market is arguably over-emphasising Hunting's risk from the Gulf and overlooking improv
Read moreOPTIONS REPORT: Traders See Anadarko Stuck In The Muck
30th Jun 2010 20:30
By Brendan Conway Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--On a day when investors retained some optimism over BP PLC's stock, options traders suggested that shares in Anadarko Petroleum Corp., a key partner in the Gulf oil spill, will stay depressed for several months. BP's stock ha
Read more